Clinical trial
Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial…
NCT00310388 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00310388 |
|---|---|
| Title | Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097 |
| Official title | A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy |
| Intervention type | Drug |
| Interventions | Retigabine (INN), Ezogabine (USAN) |
| Enrollment | 376 |
| Start date | Jul 5, 2006 |
| Primary completion | Apr 18, 2017 |
| Completion | May 24, 2018 |
| First posted | Apr 3, 2006 |
| Last update posted | Nov 15, 2018 |
| Countries | Australia, Belgium, France, Germany, Hungary, Israel, Poland, Russia, South Africa, Spain, Ukraine, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: